Signaling Self-Association of Itk Enhances T Cell Disrupting The
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Overexpression of Syk Tyrosine Kinase in Peripheral T-Cell Lymphomas
Leukemia (2008) 22, 1139–1143 & 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00 www.nature.com/leu ORIGINAL ARTICLE Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas AL Feldman1, DX Sun1, ME Law1, AJ Novak2, AD Attygalle3, EC Thorland1, SR Fink1, JA Vrana1, BL Caron1, WG Morice1, ED Remstein1, KL Grogg1, PJ Kurtin1, WR Macon1 and A Dogan1 1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 2Department of Hematology, Mayo Clinic, Rochester, MN, USA and 3Department of Histopathology, Royal Marsden Hospital, London, UK Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of Materials and methods patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed. The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression Cases of Syk PTK in 141 PTCLs. Syk was positive by immuno- We studied specimens from 141 patients with PTCL diagnosed 15 histochemistry (IHC) in 133 PTCLs (94%), whereas normal by WHO criteria. There were 86 men and 55 women of a T cells were negative. Western blot on frozen tissue (n ¼ 6) mean age of 59 years (range, 5–88 years). The study was and flow cytometry on cell suspensions (n ¼ 4) correlated with approved by the Institutional Review Board and the Biospeci- IHC results in paraffin. Additionally, western blot demonstrated mens Committee of Mayo Clinic. All patients provided informed that Syk-positive PTCLs show tyrosine (525/526) phosphory- lation, known to be required for Syk activation. Fluorescence consent for the use of their tissues for research purposes. -
ITK Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders John C
ITK Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders John C. Reneau, MD, PhD1, Steven R. Hwang, MD2, Carlos A. Murga-Zamalloa, MD1, Joseph J. Buggy, PhD3, James W. Janc, PhD3 and Ryan A. Wilcox, MD, PhD1 1University of Michigan, Ann Arbor, MI; 2Mayo Clinic, Rochester, MN; 3Corvus Pharmaceuticals, Inc., Burlingame, CA Introduction Results and Methods Conclusions • T-cell lymphomas (TCL) comprise a rare, aggressive, and Table 1: CPI-818 specifically inhibits ITK Figure 2: CPI-818 has minimal effect on normal T cells • CPI-818 is a potent ITK specific inhibitor, while CPI-893 inhibits both heterogeneous subtype of non-Hodgkin lymphoma B IC50 (nM) A ITK and RLK • Outcomes for patients with TCL remain poor and novel therapies are ITK RLK • Normal T cells express both ITK and RLK which can compensate for needed CPI-818 (ITKi) 2.3 260 inhibition of ITK function CPI-893 (ITK/RLKi) 0.36 0.4 • Engagement of the T-cell receptor (TCR) in malignant T-cells leads to • Malignant T cells almost exclusively express ITK, or express RLK at Kinome screening was performed for CPI-818 (ITKi) and CPI-893 (ITK/RLKi). CPI-818 (ITKi) had high interleukin-2-inudcible T-cell kinase (ITK) dependent activation of NF- specificity for ITK over RLK (IC50 2.3 nM and 260 nM, respectively). In contrast CPI-893 (ITK/RLKi) had a very low levels high affinity for both ITK and RLK (IC50 0.36 nM and 0.4 nM, respectively) 1 κB and GATA3, and promotes chemotherapy resistance . (A) Peripheral blood T cells from healthy donors were isolated by negative selection. -
Paxillin: a Focal Adhesion-Associated Adaptor Protein
Oncogene (2001) 20, 6459 ± 6472 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Paxillin: a focal adhesion-associated adaptor protein Michael D Schaller*,1 1Department of Cell and Developmental Biology, Lineberger Comprehensive Cancer Center and Comprehensive Center for In¯ammatory Disorders, University of North Carolina, Chapel Hill, North Carolina, NC 27599, USA Paxillin is a focal adhesion-associated, phosphotyrosine- The molecular cloning of paxillin revealed a number containing protein that may play a role in several of motifs that are now known to function in mediating signaling pathways. Paxillin contains a number of motifs protein ± protein interactions (see Figure 1) (Turner that mediate protein ± protein interactions, including LD and Miller, 1994; Salgia et al., 1995a). The N-terminal motifs, LIM domains, an SH3 domain-binding site and half of paxillin contains a proline-rich region that SH2 domain-binding sites. These motifs serve as docking could serve as an SH3 domain-binding site. Several sites for cytoskeletal proteins, tyrosine kinases, serine/ tyrosine residues conforming to SH2 domain binding threonine kinases, GTPase activating proteins and other sites were also noted. In addition, the N-terminal adaptor proteins that recruit additional enzymes into domain of paxillin contains ®ve copies of a peptide complex with paxillin. Thus paxillin itself serves as a sequence, called the LD motif, which are now known docking protein to recruit signaling molecules to a to function as binding sites for other proteins (see speci®c cellular compartment, the focal adhesions, and/ Table 1) (Brown et al., 1998a). The C-terminal half of or to recruit speci®c combinations of signaling molecules paxillin is comprised of four LIM domains, which are into a complex to coordinate downstream signaling. -
Review Tec Kinases: a Family with Multiple Roles in Immunity
Immunity, Vol. 12, 373±382, April, 2000, Copyright 2000 by Cell Press Tec Kinases: A Family Review with Multiple Roles in Immunity Wen-Chin Yang,*³§ Yves Collette,*³ inositol phosphates, but they are thought to be relevant Jacques A. NuneÁ s,*³ and Daniel Olive*² for binding of PtdIns lipids to the same sites. In most *INSERM U119 cases, PH domains bind preferentially to PtdIns (4,5)P2 Universite de la Me diterrane e and inositol (1,4,5) P3 (Ins (1,4,5) P3). However, the Btk 13009 Marseille PH domain binds PtdIns (3,4,5)P3 and Ins (1, 3, 4, 5)P4 France the tightest. PtdIns (3, 4, 5)P3, one of the products of the action of PI3K, is thought to act as a second messen- ger to recruit regulatory proteins to the plasma mem- brane via their PH domains (see below). Many of the Antigen receptors on T, B, and mast cells are multimo- mutations in Btk that lead to XLA are point mutations lecular complexes that are activated by interactions with that cluster at one end of the PH domain and could be external signals. These signals are then transmitted to predicted to impair binding to Ins (3,4,5)P (for review regulate gene expression and posttranscriptional modi- 3 see Satterthwaite et al., 1998a) (Figure 1b). Similarly, fications. Nonreceptor tyrosine kinases (NRTK) are key CBA/N xid mice carry an R28C mutation in the Btk PH players that relay and integrate these signals. NRTK are domain. The recent structure of the PH domain from divided into distinct families defined by a prototypic Btk complexed with Ins (1,3,4,5)P4 provides an explana- member: Src, Tec, Syk, Csk, Fes, Abl, Jak, Fak, Ack, tion for several mutations associated with XLA: mis- Brk, and Srm (Bolen and Brugge, 1997). -
The PX Domain Protein Interaction Network in Yeast
The PX domain protein interaction network in yeast Zur Erlangung des akademischen Grades eines DOKTORS DER NATURWISSENSCHAFTEN (Dr. rer. nat.) der Fakultät für Chemie und Biowissenschaften der Universität Karlsruhe (TH) vorgelegte DISSERTATION von Dipl. Biol. Carolina S. Müller aus Buenos Aires Dekan: Prof. Dr. Manfred Kappes Referent: Dr. Nils Johnsson Korreferent: HD. Dr. Adam Bertl Tag der mündlichen Prüfung: 17.02.2005 I dedicate this work to my Parents and Alex TABLE OF CONTENTS Table of contents Introduction 1 Yeast as a model organism in proteome analysis 1 Protein-protein interactions 2 Protein Domains in Yeast 3 Classification of protein interaction domains 3 Phosphoinositides 5 Function 5 Structure 5 Biochemistry 6 Localization 7 Lipid Binding Domains 8 The PX domain 10 Function of PX domain containing proteins 10 PX domain structure and PI binding affinities 10 Yeast PX domain containing proteins 13 PX domain and protein-protein interactions 13 Lipid binding domains and protein-protein interactions 14 The PX-only proteins Grd19p and Ypt35p and their phenotypes 15 Aim of my PhD work 16 Project outline 16 Searching for interacting partners 16 Confirmation of obtained interactions via a 16 second independent method Mapping the interacting region 16 The Two-Hybrid System 17 Definition 17 Basic Principle of the classical Yeast-Two Hybrid System 17 Peptide Synthesis 18 SPOT synthesis technique 18 Analysis of protein- peptide contact sites based on SPOT synthesis 19 TABLE OF CONTENTS Experimental procedures 21 Yeast two-hybrid assay -
Itk Promotes the Integration of TCR and CD28 Costimulation, Through Its
bioRxiv preprint doi: https://doi.org/10.1101/2020.09.11.293316; this version posted September 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Hallumi et al. 1 Article 2 Itk promotes the integration of TCR and CD28 3 costimulation, through its direct substrates, SLP-76 4 and Gads 5 Enas Hallumi1, Rose Shalah1, Wan-Lin Lo2, Jasmin Corso3, Ilana Oz1, Dvora Beach1, Samuel 6 Wittman1, Amy Isenberg1, Meirav Sela1, Henning Urlaub3,4, Arthur Weiss2,5 and Deborah 7 Yablonski1* 8 1 Department of Immunology, Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of 9 Technology, Haifa 3525433, Israel 10 2 Division of Rheumatology, Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, 11 Department of Medicine, University of California, San Francisco, San Francisco, CA, USA 12 3 Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, Am Fassberg 11, 13 37077 Göttingen, Germany 14 4 Bioanalytics, Institute for Clinical Chemistry, University Medical Center Göttingen, Robert Koch Strasse 40, 15 37075 Göttingen, Germany 16 5 Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA, USA 17 * Correspondence: [email protected] 18 Abstract: The costimulatory receptor, CD28, synergizes with the T cell antigen receptor (TCR) to 19 promote IL-2 production, cell survival and proliferation. Despite their profound synergy, the 20 obligatory interdependence of the signaling pathways initiated by these two receptors is not well 21 understood. Upon TCR stimulation, Gads, a Grb2-family adaptor, bridges the interaction of two 22 additional adaptors, LAT and SLP-76, to form a TCR-induced effector signaling complex. -
HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal -
ITK-Syk from Deregulated Lymphocyte Activation by Premature Terminal
Premature Terminal Differentiation Protects from Deregulated Lymphocyte Activation by ITK-Syk This information is current as Martina P. Bach, Eva Hug, Markus Werner, Julian Holch, of September 28, 2021. Clara Sprissler, Konstanze Pechloff, Katja Zirlik, Robert Zeiser, Christine Dierks, Jürgen Ruland and Hassan Jumaa J Immunol 2014; 192:1024-1033; Prepublished online 27 December 2013; doi: 10.4049/jimmunol.1300420 Downloaded from http://www.jimmunol.org/content/192/3/1024 Supplementary http://www.jimmunol.org/content/suppl/2013/12/26/jimmunol.130042 Material 0.DCSupplemental http://www.jimmunol.org/ References This article cites 55 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/192/3/1024.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 28, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Premature Terminal Differentiation Protects from Deregulated Lymphocyte Activation by ITK-Syk Martina P. -
Cell-Specific Protein-Tyrosine Kinase ITK: Implications for T-Cell Costimulation (Son of Sevenless/T-Cell Anergy) MONIKA RAAB*T, YUN-CAI CAI*T, STEPHEN C
Proc. Natl. Acad. Sci. USA Vol. 92, pp. 8891-8895, September 1995 Immunology p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: Implications for T-cell costimulation (son of sevenless/T-cell anergy) MONIKA RAAB*t, YUN-CAI CAI*t, STEPHEN C. BUNNELLI, STEPHANIE D. HEYECKt, LESLIE J. BERGt, AND CHRISTOPHER E. RUDD*§¶ *Division of Tumor Immunology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115; Departments of tMedicine and §Pathology, Harvard Medical School, Boston, MA 02115; and *Department of Molecular and Cellular Biology, Harvard University, 16 Divinity Avenue, Cambridge, MA 02128 Communicated by Stuart F. Schlossman, Dana-Farber Cancer Institute, Boston, MA, May 4, 1995 ABSTRACT T-cell activation requires cooperative signals 3-kinase (PI 3-kinase), T cell-specific protein-tyrosine kinase generated by the T-cell antigen receptor c-chain complex ITK (formerly EMT or TSK), and the complex between (TCRC-CD3) and the costimulatory antigen CD28. CD28 growth factor receptor-bound protein 2 and son of sevenless interacts with three intracellular proteins-phosphatidylino- guanine nucleotide exchange protein (GRB-2-SOS) (21-25). sitol 3-kinase (PI 3-kinase), T cell-specific protein-tyrosine PI 3-kinase and GRB-2 Src-homology 2 (SH2) domains bind kinase ITK (formerly TSK or EMT), and the complex between to a phosphorylated version of the Tyr-Met-Asn-Met growth factor receptor-bound protein 2 and son of sevenless (YMNM) motif within CD28 (21, 22, 25). PI 3-kinase consists guanine nucleotide exchange protein (GRB-2-SOS). -
Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene, -
Insulin Receptor Tyrosine Kinase Substrate Links the E. Coli O157:H7
Insulin receptor tyrosine kinase substrate links the E. coli O157:H7 actin assembly effectors Tir and EspFU during pedestal formation Didier Vingadassaloma, Arunas Kazlauskasb, Brian Skehana, Hui-Chun Chengc, Loranne Magouna, Douglas Robbinsa, Michael K. Rosenc, Kalle Sakselab, and John M. Leonga,1 aDepartment of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester, MA 01655; bDepartment of Virology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki University Central Hospital, FIN-00014, Helsinki, Finland; and cDepartment of Biochemistry and Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390 Edited by R. John Collier, Harvard Medical School, Boston, MA, and approved March 2, 2009 (received for review September 12, 2008) Enterohemorrhagic Escherichia coli O157:H7 translocates 2 effec- host cell plasma membrane with N- and C-terminal intracellular tors to trigger localized actin assembly in mammalian cells, result- domains and a central extracellular domain that binds to the ing in filamentous actin ‘‘pedestals.’’ One effector, the translocated bacterial outer membrane protein intimin. Clustering of Tir in the intimin receptor (Tir), is localized in the plasma membrane and host cell membrane upon intimin binding initiates a signaling clustered upon binding the bacterial outer membrane protein cascade, ultimately leading to actin pedestal formation. intimin. The second, the proline-rich effector EspFU (aka TccP) For the canonical EPEC strain, serotype O127:H6, Tir is the activates the actin nucleation-promoting factor WASP/N-WASP, only translocated effector required for pedestal formation, and and is recruited to sites of bacterial attachment by a mechanism after becoming phosphorylated on tyrosine residue 474 (Y474) dependent on an Asn-Pro-Tyr (NPY458) sequence in the Tir C- by mammalian kinases, recruits the SH2 domain-containing terminal cytoplasmic domain. -
Actin Cytoskeleton TCR-Induced Regulation of Vav and the Kinase
Kinase-Independent Functions for Itk in TCR-Induced Regulation of Vav and the Actin Cytoskeleton This information is current as Derek Dombroski, Richard A. Houghtling, Christine M. of September 24, 2021. Labno, Patricia Precht, Aya Takesono, Natasha J. Caplen, Daniel D. Billadeau, Ronald L. Wange, Janis K. Burkhardt and Pamela L. Schwartzberg J Immunol 2005; 174:1385-1392; ; doi: 10.4049/jimmunol.174.3.1385 Downloaded from http://www.jimmunol.org/content/174/3/1385 References This article cites 45 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/174/3/1385.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Kinase-Independent Functions for Itk in TCR-Induced Regulation of Vav and the Actin Cytoskeleton1 Derek Dombroski,2* Richard A.